Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Non-cash Items (2016 - 2025)

Rein Therapeutics filings provide 10 years of Non-cash Items readings, the most recent being $158000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Non-cash Items fell 90.16% year-over-year to $158000.0, compared with a TTM value of $158000.0 through Dec 2025, down 90.16%, and an annual FY2025 reading of $158000.0, down 90.16% over the prior year.
  • Non-cash Items hit $158000.0 in Q4 2025 for Rein Therapeutics, up from $153000.0 in the prior quarter.
  • The five-year high for Non-cash Items was $5.3 million in Q3 2022, with the low at $4000.0 in Q4 2021.
  • Median Non-cash Items over the past 5 years was $1.7 million (2023), compared with a mean of $1.7 million.
  • The sharpest move saw Non-cash Items crashed 99.36% in 2021, then surged 7120.52% in 2022.
  • Year by year, Non-cash Items stood at $4000.0 in 2021, then skyrocketed by 7120.52% to $288821.0 in 2022, then skyrocketed by 551.68% to $1.9 million in 2023, then decreased by 14.73% to $1.6 million in 2024, then tumbled by 90.16% to $158000.0 in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $158000.0, $153000.0, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.